Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2001;3(1):14-6.
doi: 10.1186/bcr264.

Current and future technologies for breast cancer imaging

J P Basilion  1
Affiliations
Review

Current and future technologies for breast cancer imaging

J P Basilion. Breast Cancer Res. 2001.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
In vivo MR imaging. MR image of a single mouse with TfR+ and TfR- flank tumors. (a) The T1-weighted coronal SE image (imaging time, 3.5 min; 300 × 300 × 3000 μm3 voxel resolution). TfR- tumors (right arrowhead) and TfR+ tumors (left arrowhead) have similar signal intensity. (b) Corresponding T2-weighted gradient echo image showing significant difference between TfR- and TfR+ tumors (imaging time, 8 min; 300 × 300 × 3000 μm3 voxel resolution). TfR-mediated cellular accumulation of the superparamagnetic probe decreases signal intensity as expected. These differences in MR signal intensity were most pronounced using T2- and T2*-weighted imaging pulse sequences consistent with the increased R2 upon cellular internalization. (c) Composite of a T1-weighted spin echo image obtained for anatomic detail with superimposed R2 changes after Tf-MION administration displayed in a color map. Note the difference in R2 changes between the TfR+ and TfR- tumors (asterisks). Scale bar, 10 mm; N = 1. (Reproduced with permission from Weissleder et al [13].)
See this image and copyright information in PMC

References

    1. Goldsmith MF. Leading sites of new cancer cases and deaths - 1999 estimates [letter]. JAMA. 1999;281:405. - PubMed
    1. Alexander FE, Anderson TJ, Brown HK, Forrest AP, Hepburn W, Kirkpatrick AE, Muir BB, Prescott RJ, Smith A. 14 years of follow-up from the Edinburgh randomised trial of breast cancer screening [see comments]. Lancet. 1999;353:1903–1908. - PubMed
    1. Haffty BG, Lee C, Philpotts L, Horvath L, Ward B, McKhann C, Tocino I. Prognostic significance of mammographic detection in a cohort of conservatively treated breast cancer patients [see comments]. Cancer J Sci Am. 1998;4:35–40. - PubMed
    1. Moller P, Reis MM, Evans G, Vasen H, Haites N, Anderson E, Steel CM, Apold J, Lalloo F, Maehle L, Preece P, Gregory H, Heimdal K. Efficacy of early diagnosis and treatment in women with a family history of breast cancer. European Familial Breast Cancer Collaborative Group. Dis Markers. 1999;15:179–186. - PMC - PubMed
    1. Saarenmaa I, Salminen T, Geiger U, Holli K, Isola J, Karkkainen A, Pakkanen J, Piironen A, Salo A, Hakama M. The visibility of cancer on earlier mammograms in a population-based screening programme. Eur J Cancer. 1999;35:1118–1122. - PubMed

Substances